- Chiesi Farmaceutici SPA
- Genesis Pharma SA
- Takeda Pharmaceuticals International GmbH
- Orphan Medical Inc.
- UCB Celltech
- Schwarz Pharma AG
- curasan AG
- Barrier Therapeutics Inc.
- Alliance Pharmaceuticals Ltd.
- Neopharm Ltd.
- GlaxoSmithKline PLC
- Zeneus Pharma Ltd.
- Elan Corp. PLC
- UCB SA
- Schering AG
- Bayer AG
- Shire PLC
- Allergan PLC
- GW Pharmaceuticals PLC
- Astellas Pharma Inc.
- Medigene AG
- Orphan Medical licenses Xyrem rights to Celltech
- Hoyer-Madaus gets German rights to curasan's Mitem
- Alliance and Neopharm sell Barrier's dermatology therapies
- Elan Corp. sells European sales & marketing unit to Medeus
- Beaufour Ipsen, Roche developing anticancer drugs
- UCB markets Watson's incontinence drug; terminated
- Bayer markets GW Pharmaceuticals' cannabis drug
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.